Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diazoxide for Treatment-Resistant Major Depressive Disorder
NCT02049385Phase 2Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Jan 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of diazoxide in major depressive disorder (MDD), sponsored by National Institute of Mental Health. Started Jan 2014; status: terminated.
02
Drugs
diazoxide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02049385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049385.